Abstract |
An open-label study and 2 double-blind, placebo-controlled studies have provided supporting evidence of botulinum toxin type A (BTX-A) as an effective, well-tolerated treatment for migraine. Observed durations of benefit were consistent with known properties of BTX-A. Findings suggest that response may vary by features of preinjection headaches, such as migraine frequency. The precise mechanism by which BTX-A provides pain relief is hypothesized to be related not only to acetylcholine inhibition but also to a blocking action on the parasympathetic nervous system. Additional studies that control factors likely to be related to response may lead to better understanding of the BTX-A effect on migraine and an optimal treatment protocol.
|
Authors | William J Binder, Mitchell F Brin, Andrew Blitzer, Janice M Pogoda |
Journal | Disease-a-month : DM
(Dis Mon)
Vol. 48
Issue 5
Pg. 323-35
(May 2002)
ISSN: 0011-5029 [Print] United States |
PMID | 12195263
(Publication Type: Journal Article, Review)
|
Chemical References |
- Neuromuscular Agents
- Botulinum Toxins, Type A
|
Topics |
- Blepharoptosis
(chemically induced)
- Botulinum Toxins, Type A
(administration & dosage, adverse effects, therapeutic use)
- Diplopia
(chemically induced)
- Female
- Humans
- Male
- Migraine Disorders
(drug therapy, pathology)
- Neuromuscular Agents
(administration & dosage, adverse effects, therapeutic use)
- Pain
- Randomized Controlled Trials as Topic
- Treatment Outcome
|